Navigation Links
Semafore to Present at BIO CEO & Investor Conference
Date:2/8/2008

INDIANAPOLIS, Feb. 8 /PRNewswire/ -- Semafore Pharmaceuticals Inc. today announced that Edward L. Jacobs, president and chief executive officer, and Ullrich Schwertschlag, M.D., Ph.D., chief medical officer, will present an update of the company's product development programs at 2:45 p.m. EST on Wednesday, Feb. 13, 2008, at the BIO CEO & Investor Conference in New York City.

The update will include information about Semafore's lead product candidate, SF1126, a targeted PI3 kinase inhibitor currently in Phase 1 clinical trials in solid tumors and multiple myeloma. The presentation will also include a review of the company's pipeline advancements and business development initiatives.

About SF1126

SF1126 is a small molecule conjugate containing a pan-PI3K inhibitor that selectively inhibits all PI3K class IA isoforms and other key members of the PI3K superfamily, including DNA-PK and mTOR. A major factor in tumor resistance to approved chemotherapy agents is thought to be the activation of the PI3K/PTEN pathway. As a result, it is thought that inhibiting this pathway, via SF1126, could cause the resetting of sensitivity to approved agents and exhibit synergistic anticancer effects.

About Semafore

Semafore is a clinical stage drug discovery and development company focused on small molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company's focus - cancer. Semafore is one of the first biopharmaceutical companies to focus on both PI3K and PTEN and has successfully discovered and is developing a portfolio of drug candidates addressing these targets. For more information see the company's Web site at http://www.SemaforePharma.com.

Contacts:

Corporate Media

Semafore Pharmaceuticals Inc. Russo Partners LLC

Bob Marsha
'/>"/>

SOURCE Semafore Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical to present at BIO CEO & Investor Conference
2. Genomic Health to Present at BIO CEO & Investor Conference
3. Evotec to Present at the BIO CEO & Investor Conference 2008 in New York
4. deCODE genetics to Webcast Presentation at BIO CEO and Investor Conference
5. Avicena Group to Present at 10th Annual BIO CEO & Investor Conference
6. Micromet to Present at Two Upcoming Investor Conferences
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Genelabs Technologies to Present at the BIO CEO & Investor Conference
9. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
11. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Freeslate, Inc ., the ... that Lupin Limited, one of India’s top five pharmaceutical ... PharmD System for high throughput solid form screening. ... on a wide range of quality, affordable generic and ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. ... together with two institutes from the National Institutes of ... for bringing safer, more effective treatments to patients on ... Center for Advancing Translational Sciences (NCATS) and the National ...
(Date:1/14/2014)... 2014   Kinaxis ®, provider of RapidResponse ®, a ... operations planning ( S&OP ) service, is proud to be ... will be held at the Hilton San Diego Bayfront, January ... Elisabeth Kaszas , Director of Supply Chain at Amgen, ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... CV Therapeutics,Inc. (Nasdaq: CVTX ) announced ... the Company issued new inducement stock options to,19 ... in,connection with its commercialization efforts in the United ... aggregate 119,200 shares of,common stock and are classified ...
... SectorWatch.biz announces the,availability of MarketStats on public ... today., Investors can view all of SectorWatch.biz ... -- Click on MarketStats, Today,s MarketStats on ... (OTC Bulletin Board: CVBT), Boston,Scientific Corp. (NYSE: ...
... - Atrium Innovations Inc.,(TSX: ATB) will hold its ... time on February 29, 2008. The call will ... and full year results issued earlier that,day. Participants ... numbers:,416-644-3420, 514-807-8791 or 800-731-5774 or via the Company,s ...
Cached Biology Technology:CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 2SectorWatch.biz Issues MarketStats on CVBT, BSX, MDT, CXM and DNA 2Atrium Innovations to Hold 2007 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast on February 29 2
(Date:4/17/2014)... April 17, 2014The development of stem cell therapies to ... to characterize stem cell populations based on cell surface ... a new marker that is highly expressed in a ... blood, which they describe in an article in ... Ann Liebert, Inc., publishers. The article is available free ...
(Date:4/17/2014)... N.M. A credit-card-sized anthrax detection cartridge developed at ... business makes testing safer, easier, faster and cheaper. ... anthrax, is commonly found in soils all over the ... in both humans and animals. The bacteria can survive ... B. anthracis may occur through skin contact, ...
(Date:4/17/2014)... bone marrow need to produce hydrogen sulfide in order ... a new study from the Center for Craniofacial Molecular ... USC. , Professor Songtao Shi, principal investigator on the ... the cells governs the flow of calcium ions. The ... results in osteogenesis, or the creation of new bone ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... progress on their guarantee to protect global oceans from overfishing ... 15th June) in Science , the Zoological Society of ... by governments to protect the world,s oceans and shown that ... At the World Summit on Sustainable Development in ...
... A grasshopper,s change in diet to high-energy carbohydrates while ... releases carbon dioxide into the atmosphere, according to research ... . Grasshoppers like to munch on nitrogen-rich grass ... when spiders enter the picture, grasshoppers cope with the ...
... found a surprising connection between a key DNA-repair process and ... and other chronic conditions. The discovery promises to open up ... could ultimately yield novel treatments for a wide variety of ... it goes against current dogma about the role of DNA ...
Cached Biology News:A sea of broken promises 2Predators have outsized influence over habitats 2Scientists tie DNA repair to key cell signaling network 2
... use spatulas have been designed to save ... for those interested in eliminating the recycling ... spatula is individually packaged, RNase/DNase free, non-pyrogenic ... a new product number, created to easily ...
... cytopathic effect inhibition assays, also known as ... assay measures the antibody's ability to neutralize ... types include; tissue culture supernatents; serum and ... unit is defined as the quantity of ...
... Yeast nitrogen base (YNB) is a base ... yeast media. YNB contains ammonium sulfate but does ... single-use pouches are available. Each pouch contains ... for Pichia media or 1000 ml of 10X ...
... Stem Cell Identification Kit. ... a substrate for the ... that is highly expressed ... cells, making ALDH an ...
Biology Products: